| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3999484 | Urologic Oncology: Seminars and Original Investigations | 2015 | 7 Pages |
Abstract
Treatment with sunitinib 50Â mg daily using a 2/1 dosing schedule can provide better tolerability and a longer PFS with better HRQoL in Chinese patients with mRCC than the traditional schedule 4/2.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Xiuwu M.D., Hai M.D., Yi M.D., Bing Ph.D., Xingang Ph.D., Sishun Ph.D., Jianqing M.D., Danfeng Ph.D., Lu Ph.D., Qiwei Ph.D., Lin M.D., Yi Ph.D.,